Avacta opens phase 1 trial for conjugate's efficacy regarding tumours
(Alliance News) - Avacta Group PLC on Monday announced the opening of a phase 1 trial for AVA6103, a peptide-drug conjugate. Read More
| Price | 69.00p on 18-03-2026 at 07:36:25 |
|---|---|
| Change | 0.00p 0% |
| Buy | 72.00p |
| Sell | 67.00p |
| Last Trade: | Buy 7,500.00 at 69.00p |
| Day's Volume: | 0 |
| Last Close: | 69.00p |
| Open: | 0.00p |
| ISIN: | GB00BYYW9G87 |
| Day's Range | 0.00p - 0.00p |
| 52wk Range: | 27.25p - 83.20p |
| Market Capitalisation: | £301.97m |
| VWAP: | 0.00p |
| Shares in Issue: | 437.63m |
Sector: Medicine and Biotech
Listed In: FTSE AIM All-Share,
Avacta Group (AVCT) Latest Trades |
||||
| Buy/Sell | Volume | Trade Prc | Trade Type | Trade Time |
|---|---|---|---|---|
| Buy* | 7,500 | 69.00p | Suspected BUY Trade |
16:35:16 - 17-Mar-26 |
| Sell* | 15,000 | 68.175p | Ordinary |
16:29:54 - 17-Mar-26 |
| Buy* | 500 | 68.95p | Ordinary |
16:27:50 - 17-Mar-26 |
| Buy* | 6,000 | 68.89p | Ordinary |
16:25:41 - 17-Mar-26 |
| Buy* | 1,087 | 68.95p | Ordinary |
16:24:54 - 17-Mar-26 |
| Buy* | 5,000 | 68.89p | Ordinary |
16:23:12 - 17-Mar-26 |
| Sell* | 19,939 | 68.155p | Ordinary |
16:21:44 - 17-Mar-26 |
| Buy* | 20,000 | 68.925p | Ordinary |
16:19:46 - 17-Mar-26 |
| Buy* | 10,000 | 68.925p | Ordinary |
16:18:58 - 17-Mar-26 |
| Buy* | 426 | 68.95p | Ordinary |
16:14:22 - 17-Mar-26 |
Avacta Group (AVCT) Regulatory News |
||
| Date | Source | Headline |
|---|---|---|
| 17th Mar 2026 7:00 am | RNS-R | Presentations of pre|CISION® Platform Candidates |
| 17th Mar 2026 7:00 am | RNS-R | Presentations of pre|CISION® Platform Candidates |
| 16th Mar 2026 7:00 am | RNS | Phase 1 study opening for AVA6103 |
| 16th Mar 2026 7:00 am | RNS | Phase 1 study opening for AVA6103 |
| 24th Feb 2026 7:00 am | RNS | PreCISION payload delivery advantage over ADC |
| 18th Feb 2026 7:00 am | RNS-R | Avacta to Participate in Conference March 2026 |
| 9th Feb 2026 7:00 am | RNS | Appointment of CSO |
| 3rd Feb 2026 7:00 am | RNS | Faridoxorubicin Program Clinical Updates |
| 21st Jan 2026 7:00 am | RNS | FDA Clearance of IND Application for AVA6103 |
| 20th Jan 2026 7:01 am | RNS | Year-end trading update |